Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Biocon to acquire stakes via share swaps with Serum Institute, Tata Capital, Activ Pine Shreehas Tambe to lead combined entity as CEO, managing director Biocon reviewed IPO, merger options before ...

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

Get all latest & breaking news on Biocon Biologics Limited. Watch videos, top stories and articles on Biocon Biologics Limited at moneycontrol.com.

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion. Biocon will ...

Viatris (VTRS) on Saturday said that it has entered into definitive agreements with Biocon for the sale of Viatris' equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon ...

Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses.